Canaccord Genuity Group Reiterates “Buy” Rating for Diaceutics (LON:DXRX)

Diaceutics (LON:DXRX)‘s stock had its “buy” rating reaffirmed by Canaccord Genuity Group in a research note issued to investors on Thursday, MarketBeat.com reports. They presently have a GBX 160 ($2.04) price objective on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 37.55% from the stock’s current price.

Diaceutics Stock Performance

LON:DXRX opened at GBX 116.32 ($1.48) on Thursday. The business’s 50-day moving average price is GBX 124.51 and its two-hundred day moving average price is GBX 126.72. Diaceutics has a twelve month low of GBX 84.50 ($1.08) and a twelve month high of GBX 136 ($1.73). The stock has a market cap of £98.26 million, a P/E ratio of -3,877.33 and a beta of 0.58. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 2.93.

About Diaceutics

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.